Vesomni

Vesomni is a fixed-dose combination (FDC) therapy developed by Astellas Pharma for the treatment of moderate to severe storage and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men. It combines two active substances: solifenacin succinate (6 mg), a competitive muscarinic M3 receptor antagonist, and tamsulosin hydrochloride (0.4 mg), an alpha-1A adrenergic receptor antagonist. The tamsulosin component utilizes the Oral Controlled Absorption System (OCAS) to ensure a steady release of the drug. This dual mechanism of action addresses both the bladder overactivity (storage symptoms like urgency and frequency) and the prostatic/urethral obstruction (voiding symptoms). Vesomni is typically indicated for patients who do not respond adequately to monotherapy and was extensively evaluated in the NEPTUNE Phase III clinical trial.

Brand names

VesomniUrizia

Other names

solifenacin succinate + tamsulosin hydrochloridesolifenacin + tamsulosinsolifenacin succinate/tamsulosin hydrochloride fixed-dose combination